This grant is for the purpose of funding small business organizations to develop innovative opioid and adjuvant drug combinations within a single dosage form. The primary aim is to create superior treatments for chronic pain conditions. Successful formulations should deliver enhanced pain relief compared to traditional opioid monotherapy at equivalent doses. A critical objective is to minimize opioid exposure and optimize analgesia, thereby significantly reducing the risk of addiction and mitigating the severity of common opiate adverse effects. This initiative seeks to advance safer and more effective therapeutic options for individuals suffering from chronic pain.
Opportunity ID: 247034
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PA-13-387 |
| Funding Opportunity Title: | Development of Opioid and Adjuvant Fixed Combination Dosage Forms for the Treatment of Chronic Pain with Reduced Addiction Potential (R43/R44) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.279 — Drug Abuse and Addiction Research Programs |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Nov 07, 2013 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Jan 07, 2017 |
| Current Closing Date for Applications: | Jan 07, 2017 |
| Archive Date: | Feb 07, 2017 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this announcement is to fund meritorious applications from small business organizations that aim to develop of opioid and adjuvant drug combinations within a single dosage form for treatment of a pain condition. The drug combination should provide improved analgesia when compared with the same dose (morphine equivalents) of opioid monotherapy. Such dosage forms should minimize opioid exposure while optimizing analgesia, in order to reduce risk of addiction and limit severity of other opiate adverse effects. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PA-13-387.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.279 | ADOBE-FORMS-B2 | Adobe-Forms-B2 | PKG00189011 | Mar 05, 2014 | Jan 07, 2015 | View |
| FORMS-C | Use for due dates on or after August 5, 2014 | PKG00196568 | Mar 05, 2014 | Jun 08, 2016 | View | |
| FORMS-D | Use for due dates on or after May 25, 2016 | PKG00224100 | Aug 05, 2016 | Jan 07, 2017 | View |
Package 1
Mandatory forms
247034 RR_SF424_1_2-1.2.pdf
247034 PerformanceSite_1_4-1.4.pdf
247034 RR_OtherProjectInfo_1_3-1.3.pdf
247034 RR_KeyPersonExpanded_1_2-1.2.pdf
247034 RR_Budget-1.1.pdf
247034 PHS398_CoverPageSupplement_1_4-1.4.pdf
247034 PHS398_ResearchPlan_1_3-1.3.pdf
247034 PHS398_Checklist_1_3-1.3.pdf
247034 SBIR_STTR_Information_1_1-1.1.pdf
Optional forms
247034 RR_SubawardBudget30-1.2.pdf
247034 PHS_CoverLetter_1_2-1.2.pdf
Package 2
Mandatory forms
247034 RR_SF424_2_0-2.0.pdf
247034 PHS398_ResearchPlan_2_0-2.0.pdf
247034 SBIR_STTR_Information_1_1-1.1.pdf
247034 RR_KeyPersonExpanded_2_0-2.0.pdf
247034 RR_OtherProjectInfo_1_3-1.3.pdf
247034 RR_Budget_1_3-1.3.pdf
247034 PerformanceSite_2_0-2.0.pdf
247034 PHS398_CoverPageSupplement_2_0-2.0.pdf
Optional forms
247034 RR_SubawardBudget30_1_3-1.3.pdf
247034 PlannedReport-1.0.pdf
247034 PHS398_CumulativeInclusionReport-1.0.pdf
Package 3
Mandatory forms
247034 RR_SF424_2_0-2.0.pdf
247034 PHS398_CoverPageSupplement_3_0-3.0.pdf
247034 RR_OtherProjectInfo_1_3-1.3.pdf
247034 PerformanceSite_2_0-2.0.pdf
247034 RR_KeyPersonExpanded_2_0-2.0.pdf
247034 RR_Budget_1_3-1.3.pdf
247034 PHS398_ResearchPlan_3_0-3.0.pdf
247034 SBIR_STTR_Information_1_1-1.1.pdf
Optional forms
247034 RR_SubawardBudget30_1_3-1.3.pdf
247034 PHS_Inclusion_Enrollment_Report-1.0.pdf
247034 PHS_AssignmentRequestForm-1.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
